SCHEMBL2959935

SCHEMBL2959935

CS(=O)(=O)ONC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5345895 0.77 CYP1A2 (0.35)
SCHEMBL2511148 0.77 TSHR (0.37)
SCHEMBL2136922 0.76
SCHEMBL27676666 0.76
SCHEMBL2236622 0.74
SCHEMBL9807645 0.74
Water SCHEMBL28060703 0.74 TSHR (0.35)
SCHEMBL4259788 0.74 NOS1 (0.38)
SCHEMBL1756411 0.74 TSHR (0.30)
SCHEMBL27723464 0.74 ALOX15 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113622220-A Thermal sublimation transfer paper with high production efficiency and preparation method thereof 苏州吉谷新材料有限公司 2021-11-09 CN claimed
CN-113622219-A Thermal sublimation transfer paper with high transfer rate and preparation method thereof 苏州吉谷新材料有限公司 2021-11-09 CN claimed
CN-113622221-A Thermal sublimation transfer printing paper with high transfer rate and high drying speed and preparation method thereof 苏州吉谷新材料有限公司 2021-11-09 CN claimed
CN-212758548-U Dual-cooling and cooling continuous reaction device for urea formation by using Lunatinib mesylate 南京佰麦生物技术有限公司 2021-03-23 CN claimed
CN-106573913-A Acid addition salts of Trk inhibiting compounds 小野药品工业株式会社 2017-04-19 CN claimed
CN-101550136-B Diarylurea derivatives and application thereof used for preparing anti-neoplastic medicament UNIV SHENYANG PHARMACEUTICAL 2013-06-19 CN claimed
CN-101550136-A Diarylurea derivatives and application thereof used for preparing anti-neoplastic medicament UNIV SHENYANG PHARMACEUTICAL (CN) 2009-10-07 CN claimed
EP-3728487-B1 METHOD OF REMOVING POLYMERIC MATERIAL COMPRISING HETEROATOMS FROM A SURFACE USING COMPOSITIONS INCLUDING A KETO-ESTER COMPOUND FOURTH PRINCIPLE LLC (US) 2025-07-02 EP disclosed
EP-3708633-B1 METHOD FOR RECOVERY OF CRUDE OIL ECOLAB USA INC (US) 2025-03-19 EP disclosed
US-11370996-B2 Compositions including keto-ester compounds and methods of using the same FOURTH PRINCIPLE, LLC (US) 2022-06-28 US disclosed
CN-113622220-A Thermal sublimation transfer paper with high production efficiency and preparation method thereof 苏州吉谷新材料有限公司 2021-11-09 CN disclosed
CN-113622221-A Thermal sublimation transfer printing paper with high transfer rate and high drying speed and preparation method thereof 苏州吉谷新材料有限公司 2021-11-09 CN disclosed
CN-113622221-A Thermal sublimation transfer printing paper with high transfer rate and high drying speed and preparation method thereof 苏州吉谷新材料有限公司 2021-11-09 CN disclosed
EP-1140086-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
EP-1140087-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
WO-2000035449-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed
WO-2000035451-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed
WO-2000035452-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed
WO-2000035453-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed
WO-2000035454-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed